Page 13 - Global Product Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Grants Breakthrough Therapy Designation to Genentech s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

FDA Grants Breakthrough Therapy Designation to Genentech s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSouth san franciscoLevi garrawayEuropean medicines agencyGlobal product developmentDrug administrationRoche groupBreakthrough therapy designationGlobal productTherapy designationEuropean medicines

Roche, Genentech: Inavolisib Gets FDA Breakthrough Status To Treat Breast Cancer With Mutation

Swiss drug major Roche Holding AG (RHHBY) and its U.S. Unit Genentech announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for inavolisib to treat advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Levi garrawayEuropean medicines agencyMore such health newsHead of global product developmentRoche holdingDrug administrationBreakthrough therapy designationTherapy designationChief medical officerGlobal product developmentEuropean medicines

Inavolisib Receives FDA Breakthrough Therapy Designation for PIK3CA-Mutated, HR+/HER2–Breast Cancer

Inavolisib/palbociclib/fulvestrant was granted FDA granted breakthrough therapy designation for PIK3CA-mutated, HR-positive/HER2-negative breast cancer.

Levi garrawayGlobal product development at genentechGlobal product development

Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSouth san franciscoLevi garrawayRoche groupGlobal product developmentGlobal product

Roche s Phase I Trial Of CT-388 To Treat Obesity And Type 2 Diabetes Report Positive Results

Swiss drug major Roche (RHHBY) announced Thursday positive results from the Phase I clinical trial of its dual GLP-1/GIP receptor agonist CT-388 being developed for the treatment of obesity and type 2 diabetes.

Levi garrawayMore such health newsHead of global product developmentChief medical officerGlobal product development